247.78 0.00 (0.00%)
After hours: 4:57PM EST
|Bid||247.65 x 900|
|Ask||254.00 x 1100|
|Day's range||245.27 - 249.34|
|52-week range||163.68 - 249.34|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||54.94|
|Earnings date||27-Apr-2020 - 03-May-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||266.60|
Vertex Pharmaceuticals edged lower for a third straight session, dipping intraday below a 225.76 buy point. Looks like it'll close above that 4-weeks tight entry.
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2019 and provided full-year 2020 financial guidance.
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $233.91, moving -0.3% from the previous trading session.
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).